

Piper betle extracts exhibit antitumor activity by augmenting antioxidant potential

BADRUL ALAM1,2, RAJIB MAJUMDER2, SHAHINA AKTER2 and SANG-HAN LEE1,3

1Department of Food Science and Biotechnology, Kyungpook National University, Daegu 702-701, Republic of Korea; 2Department of Pharmacy, Atish Dipankar University of Science and Technology, Dhaka 1213, Bangladesh; 3Food and Bio-Industry Research Institute, Kyungpook National University, Daegu 702-701, Republic of Korea

Received March 6, 2014; Accepted September 26, 2014

DOI: 10.3892/ol.2014.2738

Abstract. The present study was conducted to evaluate the methanolic extract of Piper betle leaves (MPBL) and its organic fractions with regard to antitumor activity against Ehrlich ascites carcinoma (EAC) in Swiss albino mice and to confirm their antioxidant activities. At 24 h post-intraperitoneal inoculation of tumor cells into mice, extracts were administered at 25, 50 and 100 mg/kg body weight for nine consecutive days. The antitumor effects of the extracts were then assessed according to tumor volume, packed cell count, viable and non-viable tumor cell count, median survival time and increase in life span of EAC-bearing mice. Next, hematological profiles and serum biochemical parameters were calculated, and antioxidant properties were assessed by estimating lipid peroxidation, reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) levels. MPBL and the ethylacetate fraction (EPBL) at a dose of 100 mg/kg induced a significant decrease in tumor volume, packed cell volume and viable cell count and increased the life span of the EAC-bearing mice (P<0.05). Hematological and serum biochemical profiles were restored to normal levels in the extract-treated mice compared with the EAC control mice. MPBL and EPBL treatment significantly decreased lipid peroxidation (P<0.05) and restored GSH, SOD and CAT levels towards normal compared with the EAC control. Taken together, the results of the present study demonstrated that Piper betle extracts exhibit significant antitumor activity, which may be attributed to the augmentation of endogenous antioxidant potential.

Introduction

Free radicals [reactive oxygen species (ROS) and reactive nitrogen species] are products of normal cellular metabolism, and are extremely reactive and potentially damaging transient chemical species. Numerous endogenous metabolic processes involving redox enzymes and bioenergetic electron transfer generate free radicals, which aid in the conversion of normal cells to cancerous cells (1). ROS are able to affect a number of significant biological molecules, including DNA, proteins and lipids, leading to a number of degenerative diseases, including cancer, Alzheimer’s disease, arthritis and ischemic reperfusion (2). The oxidative damage to DNA may be reduced by antioxidant-rich diets, thus preventing the onset of carcinogenesis (3). In addition, the increasing incidence of cancer and the lack of anticancer drugs has resulted in the pharmacological and chemical investigation of anticancer agents obtained from medicinal plants. At present, >100 novel products obtained from natural sources are in clinical development, particularly as anticancer agents and anti-infectives (4).

Betelvine (Piper betle) belongs to the Piperaceae family, which is regarded as a medicinal plant in Southeast Asia. The leaves of Piper betle have been found to exhibit wound healing (5), hepatoprotective (6), antioxidant and antifertility effects, as well as antimitoty effects on washed human spermatozoa (7). The primary constituent of the leaves is a volatile oil that contains phenols, betel-phenol, chavibetol, chavicol, cadinene and hydroxycavicol, which have been found to exhibit antioxidant and anticarcinogenic activities (8-10). In Bangladesh, the tribal population and aborigines chew these leaves as a narcotic, which causes fainting, profuse sweating and provides body warmth during winter (7).

The present study was performed to evaluate the antioxidant and antitumor activity of the methanolic extract of Piper betle leaves (MPBL) and its organic soluble fractions against Ehrlich ascites carcinoma (EAC) in mice.

Material and methods

Plant materials. The leaves of Piper betle L. were collected from Jahangirnagar University campus, (Dhaka, Bangladesh) in February 2012. The plant material was taxonomically identified by the National Herbarium of Bangladesh (Dhaka, Bangladesh) and recorded as voucher specimen no. JU/3334 for future reference.

Chemicals. Bovine serum albumin and bleomycin were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Trichloroacetic acid was acquired from Merck (Mumbai, India), and thiobarbituric acid (TBA) and nitroblue tetrazo- 
lum chloride were purchased from Loba Chemie Pvt. Ltd., 
(Mumbai, India). 5,5’-Dithiobis-(2-nitro benzoic acid), phena- 
zonium methosulfate, nicotinamide adenine dinucleotide 
and reduced glutathione (GSH) were purchased from Sisco 
Research Laboratories Pvt., Ltd., (Mumbai, India). All other 
chemicals and reagents used were of the highest analytical 
grade.

Preparation of plant extract. The plant material was shade-dried 
with occasional shifting and then ground to a powder using 
a mechanical grinder, passed through a #40 sieve (mesh 
size, 0.425 µm) and stored in an air-tight container. A total of 
1.0 kg of dried powder material was refluxed with MeOH for 
3 h, then the total filtrate was concentrated until dry in vacuo 
at 40˚C to render the MeOH extract (240.0 g). The extract was 
subsequently suspended in dH2O and successively partitioned 
with chloroform (CHCl3) and ethylacetate (EtOAc) to supply the 
CHCl3 (90.0 g) and EtOAc (50.0 g) fractions, respectively, and 
the H2O residue (100.0 g).

Animals. A total of 121 female, 6-7 week-old, Swiss albino 
mice (weight range, 25-30 g) were used to assess biological 
activity. The animals were maintained under standard labora- 
tory conditions and had access to food and water ad libitum. 
The animals were acclimatized to the environment for seven 
days prior to the experimental procedures. All animal experi- 
ments were performed in accordance with the guidelines of 
the Institutional Animal Ethics Committee of Atish Dipankar 
University of Science and Technology, Dhaka, Bangladesh. 
Animal treatment and maintenance for acute toxicity and 
anticancer effects were conducted in accordance with the 
Principle of Laboratory Animal Care (NIH publication No. 
85-23, revised 1985) and the Animal Care and Use Guidelines 
of Atish Dipankar University of Science and Technology.

Acute toxicity study. An acute oral toxicity assay was 
performed using healthy, non-pregnant, adult female, Swiss 
albino mice (weight range, 25-30 g) divided into six different 
groups. Increasing oral doses of MPBL (50, 100, 200, 500 
and 1,000 mg/kg body weight) in distilled water were admin- 
istered at 20 ml/kg to the different test groups. The normal 
group received distilled water only. Following treatment, the 
animals were allowed to feed ad libitum and observed for 48 h 
for any mortality or behavioral changes (11).

Tumor transplantation. EAC cells were obtained from the 
Indian Institute of Chemical Biology (Calcutta, India). The EAC 
cells were maintained in vivo in Swiss albino mice by intra- 
peritoneal (i.p.) transplantation of 2x10^6 cells per mouse every 
10 days. Ascitic fluid was drawn from the EAC tumor-bearing 
mice at the log phase (days 7-8 of tumor-bearing) of the tumor 
cells and each test animal received 0.1 ml of i.p. tumor cell 
suspension containing 2x10^6 tumor cells.

Treatment schedule. The animals were divided into eight 
groups (n=12) and provided with food and water ad libitum. All 
animals in each group received EAC cells (2x10^6 cells/mouse 
i.p.) with the exception of group-I, which served as the normal 
saline control (5 ml/kg body weight i.p.). Group II served as 
the EAC control. At 24 h post-EAC transplantation, groups III, 
IV and V received MPBL at doses of 25, 50 and 100 mg/kg i.p., 
respectively. Groups VI and VII also received CHCl3 (CPBL) 
and EtOAc (EPBL) extract at doses of 100 mg/kg i.p., whereas 
group VIII, serving as a positive control, received bleo- 
mycin (0.3 mg/kg i.p.) for nine consecutive days (12). At 24 h 
post-administration of the last dose, the animals were fasted for 
18 h, at which point, six animals in each group were sacrificed 
bys cardiac puncture for the estimation of hematological and 
surgical biochemical parameters, and to measure antitumor and 
liver biochemical parameters. The remainder were provided 
with food and water ad libitum and observed to determine if 
there were any changes in lifespan. The antitumor activity of 
the extract was measured in the EAC animals as described next.

Determination of tumor and packed cell volume. The mice 
were dissected and ascitic fluid was collected from the perito- 
eal cavity. The tumor volume was measured using a graduated 
centrifuge tube and the packed cell volume was determined by 
centrifuging the fluid at 1,000 g for 5 min.

Viable and non-viable tumor cell count. The ascitic fluid 
was collected in a white blood cell (WBC) pipette and diluted 
100 times. A drop of the diluted suspension was then placed on a 
Neubauer counting chamber (Celeromics, Cambridge, UK) and 
the cells were stained with Trypan blue (0.4% in normal saline). 
The cells that did not take up the dye were considered viable, 
whereas those that did were considered non-viable. The viable and 
non-viable cells were then counted using the following formula: 
Cell count = (number of cells x dilution factor) / (area x thick- 
ness of liquid film).

Determination of median survival time (MST) and percentage 
increase in life span. The rate of mortality was monitored by 
recording the percentage increase in life span (% ILS) and MST 
according to the following formula (13): MST = days = (day of 
first mortality + day of last mortality) / 2.

Estimation of hematological and serum biochemical parameters. 
Blood was collected to estimate the hemoglobin (Hb) content, 
and red blood cell (RBC) and WBC counts (12). Differential 
counts of WBCs were performed from Leishmen-stained blood 
smears (13). Serum biochemical parameters, including serum 
glutamate oxaloacetate transaminase (SGOT), serum glutamate 
pyruvate transaminase (SGPT) (14), serum alkaline phospha- 
tase (SALP), serum bilirubin (15) and total protein (16) levels 
were also estimated.

Estimation of lipid peroxidation thiobarbituric acid reactive 
substances (TBARS). The TBARS in the liver tissue were 
measured as described by Ohkawa et al (17) and expressed as 
µmols of malondialdehyde (MDA)/g of liver tissues.

Estimation of reduced GSH level. The GSH level of liver tissue 
was determined as described by Ellman (18) and expressed as 
µg/g of liver tissues.

Estimation of superoxide dismutase (SOD) and catalase 
(CAT) levels. The SOD and CAT activity in the liver tissue
was analyzed according to the methods described by Pari and Latha (19). The SOD activity was expressed as U/mg of liver tissue and CAT was expressed in terms of µmol of hydrogen peroxide decomposed/min/mg of liver tissue.

Statistical analysis. All values are expressed as the mean ± standard error of the mean of three replicate experiments. Statistical analysis was performed using the SPSS version 16.0 software (SPSS Inc., Chicago, IL, USA). All in vivo data were assessed using analysis of variance followed by Dunnett's test and P<0.05 was considered to indicate a statistically significant difference.

Results

Acute toxicity studies. Acute toxicity studies are primarily designed to develop therapeutic indices, for example, the ratio between the pharmacologically effective dose and lethal dose against the same strain and species. MPBL was safe at doses as high as 1,000 mg/kg [per os (p.o.)] body weight, causing no mortality, behavioral changes, locomotor ataxia, diarrhea or weight loss in mice during 48 h of observation. Additionally, food and water intake did not differ among the groups studied (data not shown).

Tumor growth and survival parameters. MPBL and EPBL at a dose of 100 mg/kg body weight significantly reduced the body weight, tumor volume, packed cell volume and viable tumor cell count (Fig. 1), however, the non-viable tumor cell count was increased compared with the EAC control group (data not shown). However, CPBL exerted no significant effects at a dose of 100 mg/kg. The MST increased to 22.31±0.11 (% ILS, 10.99), 29.01±0.17 (% ILS, 44.25) and 33.23±0.21 days (% ILS, 65.25) following the administration of MPBL at doses of 25, 50 and 100 mg/kg body weight, respectively, while the EPBL and the reference drug, bleomycin, exhibited survival times of 36.23±0.31 (% ILS, 80.15) and 37.60±0.11 days (% ILS, 86.97), respectively (Fig. 1). Finally, the change in body weight (data not shown) of the animals indicated that *Piper betle* extracts had the potential to inhibit tumor growth.

Hematological parameters. The hematological parameters of the tumor-bearing mice were found to be significantly different compared with the normal group. The total WBC count increased (P<0.05) and the Hb content and RBC count decreased in the EAC control group compared with the normal saline group. Treatment with MPBL and EPBL at a dose of 100 mg/kg body weight significantly increased the Hb content and RBC count towards normal levels (data not shown). Additionally, the number of neutrophils (Fig. 2A) was increased, while the numbers of lymphocytes (Fig. 2B) and monocytes (Fig. 2C) were found to decrease in the EAC control group compared with the normal group. These results indicated that treatment with varying doses of *Piper betle* extract could significantly change these altered parameters to near normal values (Fig. 2).

Effect on biochemical parameters. As shown in Table I, the biochemical parameters, including SGOT, SGPT, SALP and bilirubin levels, in the EAC control group were significantly upregulated compared with the normal group. Treatment with MPBL and EPBL at doses of 100 mg/kg significantly decreased the SGOT, SGPT, SALP and bilirubin levels to approximately normal levels, whereas CPBL at this dose did not produce the optimum results. The total protein level was significantly decreased in the EAC control animals compared with the normal group. These results indicated that treatment with varying doses of *Piper betle* extract could significantly change these altered parameters to near normal values.

Effect on lipid peroxidation and reduced GSH. Following administration of 100 mg/kg MPBL or EPBL, or 0.3 mg/kg bleomycin to the EAC-bearing mice, the level of lipid peroxidation decreased by 91.34±1.10, 82.34±1.10 and 167.21±1.04 µM/g, respectively, compared with the EAC control group (166.19±3.06 µM/g of wet liver tissue; P<0.05;
ALAM et al: Piper betle EXHIBITS ANTITUMOR ACTIVITY

Fig. 3A). Reduced GSH levels (39 µg/g of wet liver tissue) were found to be significantly elevated towards the normal level upon administration of MPBL and EPBL at 100 mg/kg compared with the EAC control group (P<0.05; Fig. 3B).

Effect on SOD and CAT. The administration of MPBL at a dose of 25, 50 and 100 mg/kg markedly increased the levels of SOD and CAT in a dose-dependent manner (P<0.05; Fig. 3C and D) compared with the EAC control group. By contrast, EPBL exhibited almost the same activity as standard bleomycin for the two parameters (Fig. 3).

Discussion

Initially reported as a spontaneous murine mammary adenocarcinoma, the Ehrlich tumor can be grown in the majority of mouse strains and is accepted as a transplantable tumor model to examine the antitumor effects of a number of substances (20).

In the present study, a rapid increase in ascitic tumor volume was observed in EAC tumor-bearing mice and the treatment with Piper betle extracts reduced the intraperitoneal tumor burden, thereby reducing the tumor volume, tumor weight and viable tumor cell count, while increasing the life span of the tumor-bearing mice. Therefore, it may be hypothesized that the increase in lifespan of EAC-bearing mice in response to MPBL and EPBL at 100 mg/kg may be due to a decrease in nutritional fluid volume and a delay in cell division (12).

Reductions in viable cell count and increased non-viable cell count towards normal in tumor hosts indicate antitumor effects against EAC cells in mice. These results indicate that MPBL and EPBL have a direct association with tumor cells at higher doses as they absorb the anticancer drug by direct absorption in the peritoneal cavity, resulting in lysis of the cells via a direct and cytotoxic mechanism. Anemia and myelosuppression have frequently been observed in ascites carcinoma due to a deficiency in iron, in hemolytic or myelopathic conditions, resulting in a reduced number of RBCs (21). In the present

---

Table I. Effects of Piper betle on serum biochemical parameters in EAC-bearing mice.

| Group, n | SGOT, IU/l | SGP, IU/l | SALP, IU/l | Total protein, mg/dl | Bilirubin, mg/dl |
|---------|------------|-----------|------------|----------------------|-----------------|
| I       | 38.32±1.41 | 28.02±4.32 | 77.91±2.24 | 9.67±0.24            | 0.91±0.19       |
| II      | 74.12±1.11 * | 66.32±5.32 * | 120.11±3.24 * | 5.78±0.14 *          | 3.75±0.12 *     |
| III     | 65.52±3.51 a | 52.12±5.12 a | 108.31±1.24 a | 6.08±0.19 a           | 2.85±0.75 a     |
| VI      | 42.52±5.11 b | 43.32±3.22 b | 97.19±5.24 b | 6.18±0.34 b           | 2.15±0.18 b     |
| V       | 38.12±1.01 b | 39.39±1.12 b | 88.10±1.27 b | 6.98±1.34 b           | 1.75±1.18 b     |
| VI      | 55.52±3.51 b | 48.12±5.12 b | 101.31±1.24 b | 6.78±0.19 b           | 2.35±0.75 b     |
| VII     | 34.12±1.01 b | 36.39±1.12 b | 83.10±1.27 b | 7.78±1.34 b           | 1.25±1.18 b     |
| VIII    | 35.13±1.91 b | 33.01±1.31 b | 73.90±1.92 b | 8.38±1.14 b           | 0.98±1.18 b     |

Data is presented as mean ± standard error of the mean (n=6 mice per group). *P<0.05 vs. normal saline group. aP<0.05 vs. EAC control group. Group I animals were administered normal saline (5 ml/kg), whereas group II received EAC control (2x10⁶ cell/mouse), group VIII received bleomycin, 0.3 mg/kg body weight, and groups III, IV and V were treated with 25, 50 and 100 mg/kg body weight (p.o.) of MPBL, respectively. Groups VI and VII were treated with 100 mg/kg body weight (p.o.) of CPBL and EPBL, respectively. EAC, Ehrlich ascites carcinoma; p.o., per os; SGOT, serum glutamate oxaloacetate transaminase; SGPT, serum glutamate pyruvate transaminase; SALP, serum alkaline phosphatase.

---

Figure 2. A classical feature of Piper betle extracts on differential count of WBCs; (A) neutrophils, (B) lymphocytes and (C) monocytes. The data are presented as the mean ± standard error of the mean (n=6 mice per group), *P<0.05 vs. normal saline group. aP<0.05 vs. EAC control group. Group I animals received normal saline (5 ml/kg), whereas group II received EAC control (2x10⁶ cell/mouse), group VIII received bleomycin, 0.3 mg/kg body weight, and groups III, IV and V were treated with 25, 50 and 100 mg/kg body weight (p.o.) of MPBL, respectively. Groups VI and VII were treated with 100 mg/kg body weight (p.o.) of CPBL and EPBL, respectively. EAC, Ehrlich ascites carcinoma; p.o., per os; MPBL, methanolic extract; CPBL, chloroform; EPBL, ethylacetate fraction.
study, treatment with *Piper betle* extracts returned the hemoglobin content and RBC and WBC counts to almost normal levels (data not shown), indicating that the extracts exhibit hematopoietic protecting activity without myelotoxicity, the most common side-effect of cancer chemotherapy.

A preliminary phytochemical study indicated the presence of alkaloids, steroids, tannins, phenolic and flavonoid compounds and glycosides in crude extracts of *Piper betle* (7). A number of studies have indicated that the presence of steroids, terpenoids and phenolic compounds, including coumarins, tannins and flavonoids, exert a chemopreventive role in the progression of cancer by affecting signal transduction in cell proliferation and angiogenesis (22). Incorporation of phytosterols into the cell membrane can alter the fluidity of membranes and the activity of membrane-bound enzymes. In addition, phytosterols cause alterations in pathway signal transduction, resulting in the growth of tumors and the stimulation of apoptosis in tumor cell lines. Phytosterols have been demonstrated to enhance the *in vitro* proliferation of human peripheral blood lymphocytes and T cells, indicating the possible stimulation of the immune system (23). The marked anticancer activities of MPBL and EPBL are possibly due to the presence of alkaloids, phenolic compounds, flavonoids and terpenoids, and their synergistic effects.

ROS exhibit multiple functions and are involved in tumor initiation and progression (24). MDA, a free oxygen radical product formed during oxidative degeneration of cancerous tissues (25) and as the end product of lipid peroxidation, is a biomarker of oxidative stress that has been reported to be exhibited at higher levels in cancer tissues than in normal tissues (26). The results of the present study indicated that the TBARS levels in the cancerous tissues were higher than those in the normal tissues (Fig. 3). Treatment with EPBL inhibited hepatic lipid peroxidation, as indicated by the reduction of MDA levels toward normal levels, emphasizing the reduction in free radical production and the subsequent decrease in damage to the cell membrane and MDA production in the tumor-bearing mice.

Depleted endogenous antioxidant enzyme levels with enhanced free radical generation have been well documented in carcinogenesis (27). Numerous tumor cells with pro-oxidant status promote oxidative stress, which increases the surviving potential of the cancer cells by inducing mutations, activating redox signaling and stimulating pro-survival factors, such as nuclear factor-κB and activator protein-1 (28). GSH, which strongly inhibits the neoplastic process, is important in the endogenous antioxidant system. This compound acts mainly as a reducing agent and detoxifies hydrogen peroxide when GSH peroxidase is present (29). In the current study, the GSH levels in the experimental mice were found to be significantly lower than those in the EAC control mice (Fig. 3). These results revealed that the antitumor activity of MPBL and EPBL was accompanied by the enhancement of non-enzymatic antioxidant protection.

It is well-known that cells exhibit enzymatic antioxidant mechanisms, such as the generation of SOD and CAT, which are involved in the elimination of free radicals (30). SOD and CAT are involved in the scavenging of superoxide and hydrogen peroxide. In a previous study, decreased levels of SOD activity were detected in EAC-bearing mice in response to the loss of Mn²⁺-SOD activity and mitochondria in EAC cells, resulting in a decrease in the amount of total SOD activity in the liver (31). The inhibition of SOD and CAT activity as a consequence of tumor growth has also been reported (32). Similar findings were observed in the present study on EAC-bearing mice. The administration of MPBL and EPBL at higher doses increased the SOD and CAT levels towards normal levels.

Plant-derived extracts with antioxidant potential have demonstrated cytotoxicity against tumor cells and antitumor activity in experimental animals (33). The cytotoxic and
antitumor activity of plant-derived products occurs either through the induction of apoptosis or the inhibition of neovascularization (34). In the present study, higher doses of MPBL and EPBL dramatically reduced tumor growth and the viability of the tumor cells, and normalized the hematological and serum biochemical profiles, increasing the life span compared with the EAC control mice. MPBL and EPBL treatment improved the endogenous non-enzymatic and enzymatic antioxidant systems (Fig. 3). The decrease in lipid peroxidation and the elevation of GSH, SOD and CAT levels in the MPBL- and EPBL-treated mice indicated the potential of *Piper betle* extract as an inhibitor of EAC-induced intracellular oxidative stress.

In conclusion, *Piper betle* leaf extracts exhibited marked antitumor activity against EAC in the mice of the present study, possibly by modulating lipid peroxidation and augmenting endogenous antioxidant defense systems. Future studies are required to investigate the isolation and characterization of lead compounds responsible for the aforementioned activity of this plant.

Acknowledgments

The authors would like to thank Professor M. Ekramul Haque (Department of Pharmacy, Rajshahi University, Rajshahi, Bangladesh) for providing the EAC cells.

References

1. Rajkumar V, Guha G and Kumar RA: Antioxidant and anti-neoplastic activities of *Picrohiza kurroa* extracts. Food Chem Toxicol 49: 363-369, 2011.
2. Suja KP, Jayalekshmy A and Arumughan C: Free radical scavenging behavior of antioxidant compounds of sesame (*Sesamum indicum*) in DPPH system. J Agric Food Chem 52: 912-915, 2004.
3. Meyskens FL Jr and Szabo E: Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev 14: 1366-1369, 2005.
4. Murukami A, Ali AM, Mat-Salleh K, Koshimizu K and Ohigashi H: Screening for the in vitro anti-tumor-promoting activities of edible plants from Malaysia. Biosci Biotechnol Biochem 64: 11-16, 2000.
5. Santhanam G and Nagarajan S: Wound healing activity of *Curcuma aromatica* and *Piper betle*. Fitoterapia 61: 458-459, 1990.
6. Saravanan R, Prakasham A, Ramesh B and Pugalendi KV: Influence of *Piper betle* on hepatic marker enzymes and tissue antioxidant status in ethanol-treated Wistar rats. J Med Food 5: 197-204, 2002.
7. Choudhary D and Kale RK: Antioxidant and non-toxic properties of *Piper betle* leaf extract: in vitro and in vivo studies. Phytother Res 16: 461-466, 2002.
8. Bhide SV, Zariwala MB, Amonkar AJ and Azuine MA: Chemo-preventive efficacy of betel leaf extract against benzo[a]pyrene-induced fore-stomach tumors in mice. J Ethnopharmacol. 34: 207-213, 1991.
9. Garg SC and Jain R: Biological activity of the essential oil of *Piper betle*. J Essent Oil Res 23: 601-602, 1990.
10. Singh M, Shukla S, Soni VK, et al: The n-hexane and chloroform fractions of *Piper betle* trigger different arms of immune responses in BALB/c mice and exhibit antifilarial activity against human lymphatic filarial *Brugia malayi*. Int Immunopharmacol 9: 716-728, 2009.
11. Zahan R, Alam MB, Islam MS, et al: Anticancer Activity of *Alangium salviifolium* flower in Ehrlich ascites carcinoma bearing mice. Int J Cancer Res 7: 254-262, 2011.
12. Sur P, Bag SP and Khamam JA: Choraoacetohydroxyacidic acid as antitumor agent against Ehrlich ascites carcinoma in mice. Neoplasma 44: 197-201, 1997.
13. Gupta M, Mazumder UK, Kumar RS, et al: Antitumor activity and antioxidant status of *Caesalpinia bonduc* against Ehrlich ascites carcinoma in Swiss albino mice. J Pharmcol Sci 94: 177-184, 2004.
14. Bergmeyer HU, Scelle P and Wahlefeld AW: Optimization of methods for ascorbate and catalase and glutathione peroxidation. Clin Chem 24: 58-70, 1978.
15. Malloy HT and Evelyn KA: The determination of bilirubin with the photometric colorimeter. J Biol Chem 119: 481-490, 1937.
16. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin-phenol reagent. J Biol Chem 193: 265-275, 1951.
17. Ohkawa H, Onishi N and Yagi K: Assay for lipid peroxidation in animal tissue by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1979.
18. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77, 1959.
19. Pari L and Latha M: Protective role of *Scoparia dulcis* plant extract on brain antioxidant status and lipid peroxidation in STZ diabetic male Wistar rats. BMC Complement Altern Med 4: 16, 2004.
20. Segura JA, Barbero LG and Márquez J: Ehrlich ascites tumor unbalances splenic cell populations and reduced responsiveness of T cells in *Staphylococcus aureus* enterotoxin B stimulation. Immunol Lett 74: 111-115, 2000.
21. Opare Kennedy D, Kojima A, Hasuma T, et al: Growth inhibitory effects of green tea extract and (−)-epigallocatechin in Ehrlich ascites tumour cells involves a cellular thiol-dependent activation of mitogenic-activated protein kinases. Chem Biol Interact 134, 113-133, 2001.
22. Blois MS: Antioxidant determination by the use of a stable free radical. Nature 181: 1199-1200, 1958.
23. Jones PJ and AbuMweis SS: Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Curr Opin Clin Nutr Metabol Care 12: 147-151, 2009.
24. Valko M, Leibfritz D, Moncol J, et al: Free radicals and antioxidant status in normal human tissues. Cancer Res 42: 1955-1961, 1982.